FDA Approves Blood Test for Early Alzheimer’s Risk Detection Using Neutrophil Inflammation Marker
The FDA approved the Lumipulse G pTau217/ß-Amyloid 1-42 blood test for early Alzheimer’s detection in adults 55+ with cognitive decline.
Read MoreALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
The FDA approved the Lumipulse G pTau217/ß-Amyloid 1-42 blood test for early Alzheimer’s detection in adults 55+ with cognitive decline.
Read More